Published by Josh White on 6th May 2025
(Sharecast News) - AstraZeneca announced on Tuesday that it has secured European Commission approval for 'Calquence', or acalabrutinib, in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplant.